Clinical Trial

Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial

Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-04; most recent amendment 2026-04-09.
Status change: Not Yet Recruiting → Recruiting 2025-12-08
Trial Details
NCT Number NCT06923397
Lead Sponsor Dana-Farber Cancer Institute
Conditions Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin, Sedentary Behavior
Enrollment 24 participants
Start Date 2025-06-05
Primary Completion 2026-11-28 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13